# A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

> **NCT00405743** · PHASE1,PHASE2 · COMPLETED · sponsor: **Clavis Pharma** · enrollment: 153 (actual)

## Conditions studied

- Hematologic Malignancies
- AML

## Interventions

- **DRUG:** CP-4055
- **DRUG:** CP-4055

## Key facts

- **NCT ID:** NCT00405743
- **Lead sponsor:** Clavis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-05
- **Final completion:** 2010-05
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2013-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00405743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00405743, "A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00405743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*